Clinical trial · Observational
Personal Health Train for Radiation Oncology in India and The Netherlands
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary and general objective of this protocol as the current standard of care is to improve the quality of radiotherapy for HNC patients. This will ultimately be achieved by optimizing locoregional tumour control and overall survival and by reducing radiation-induced side effects. It will also allow the assessment of the effects of newly introduced radiation technology (e.g. proton therapy) for this particular group of patients. The clinical introduction of this standard follow-up program (SFP) will allow for a systematic and broad scale quality improvement cycle for HNC patients treated with radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Carcinoma | Head and Neck Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 2 years
Secondary outcomes (3)
- measure
- Recurrence
- timeFrame
- 2 years
- measure
- Distant metastases
- timeFrame
- 2 years
- measure
- Treatment-related adverse events
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC) * Head and Neck primary tumor site: oral cavity, oropharynx, larynx or hypopharynx * Treated between 01-2008 and 12-2017 * Clinical stage III and IV (a, b) according to TNM 7th edition * No distant metastases (M0) * Treated with curative intent: primary definitive radiation therapy with or without systemic treatment * Availability of baseline imaging: * Planning CT scan of the HN region in treatment position, with RT-structures available, performed with contiguous cuts of 2-3 mm or less in slice thickness with i.v. contrast * (if available) FDG-PET in treatment position Exclusion Criteria: * Any previous HNC * Patients with previous malignancies in the last 5 years before treatment for HNC, with the exception of surgically cured carcinoma in situ of the cervix, in situ breast cancer, incidental finding of stage T1a or T1b prostate cancer, and basal/squamous cell carcinoma of the skin * Any previous malignancy that was treated with surgery and/or radiation of the head and neck region * Histological type other than HNSCC * Cancers originating in the oral cavity, nasopharynx, salivary glands or sinonasal area * Postoperative radiation treatment setting
References
Publications (0)
Data not yet available